ABSTRACT
T-cell large granular lymphocytic leukemia is defined in the 2008 World Health Organization (WHO) classification as a persistent increase in T-cell large granular lymphocytes (LGLTs) at greater than 2.0 × 10 9 /L in the blood without a known cause. 1 Some investigators feel that this is better regarded as a T-cell clonopathy of undetermined significance due to its often indolent clinical course. 2, 3 With new techniques that can detect T-cell clones at lower levels, the criteria for LGLT leukemia have evolved so that now cases with more than 0.5 × 10 9 /L clonal LGLT cells and associated clinical disease may be considered LGLT leukemia. 4, 5 As ever smaller clones are being detected with more sensitive technology, the distinction of these from LGLT leukemia is evolving. 6 We performed sensitive flow cytometry to detect LGLT clones and correlated these with clinical disease. On the basis of this review, we propose three categories of LGLT clones: (1) T-cell clones of undetermined significance (TCUS), (2) LGLT leukemia, and (3) T-cell immunoclones (TICs).
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© American Society for Clinical Pathology the same specimen), or high indexes of clinical suspicion for the possibility of clonal LGLT. Cases were excluded from analysis if there were known histories of prior transplants (bone marrow or solid organs) or of other neoplasms, unless there were high indexes of clinical suspicion for the possibility of concomitant LGLT clones. This study was approved by the institutional review board of the University of Minnesota and is in accord with the Helsinki Declaration of 1975.
The routine eight-color screening panel by flow cytometry (three-laser FACSCanto II; Becton Dickinson, Franklin Lakes, NJ) included CD2, CD3, CD4, CD5, CD7, CD8, CD45, and CD56 (Becton Dickinson; Beckman Coulter, Brea, CA) with fluorochromes fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5), phycoerythrin-cyanin 7 (PE-Cy7), allophycocyanin (APC), allophycocyanin-cyanin 7 (APC-H7), V450, and V500. In most cases, this panel was expanded to include CD16 and CD57. The LGLTs were quantitated as CD3-positive T cells expressing CD16, CD56, or CD57. The antibodies were added to whole blood or marrow after adjusting cellular concentrations, and the erythrocytes were lysed with ammonium chloride. The immunophenotypes of the LGLT clones were compared with that of normal T lymphocytes in the same specimen.
For cases fulfilling the selection criteria, additional analyses were performed for the T-cell receptors ab and gd and for Vb. After lysing erythrocytes with ammonium chloride, Vb analysis by flow cytometry was performed in four colors with CD3 and CD8 or in five or six colors if additional antibodies (CD4, CD5, CD56, etc) were needed to gate LGLT populations with aberrant immunophenotypes. The Vb kit (IOTest Beta Mark; Beckman Coulter) has eight cocktails with 24 antibodies (Vbs 1, 2 24 Vbs expressed by less than 30% of a gated population since these antibodies should stain 70% of T lymphocytes. [7] [8] [9] This
Vb analysis was applied only to T cells expressing the ab T-cell receptor.
Medical charts were reviewed for clinical findings present concurrently with the LGLT clones. These included the patient age, blood hemoglobin, WBC count, neutrophil count, platelet count, marrow cellularity, splenomegaly, transplants (bone marrow or solid organs), autoimmune disorders, and neoplasms. The medical charts were reviewed for treatment, survival, and cause of death.
Results

Immunophenotype by Flow Cytometry
Fifty-four (20%) of 264 patients with testing by Vb had clonal abnormalities. The LGLT clones were CD4-/CD8+ in 67% (36/54), CD4+/CD8-in 9% (5/54), CD4+/CD8+ in 19% (10/54), and CD4-/CD8-in 6% (3/54) ❚Table 1❚. CD57 was positive in 96% (52/54). Coexpression of CD16 and CD57 was found in 32% (15/ The percentage of the LGLT clone in the marrow is shown as a percentage of LGLT cells in the aspirated marrow leukocytes (%MC) and as a percentage of marrow space (%MS) ❚Figure 2❚, although these percentages may not always be representative because of hemodilution. The %MS was calculated by multiplying the %MC by the percent marrow cellularity in the trephine biopsy. The %MS provided a better estimate of the clone size than did the %MC. For example, one patient with 33% MC had only 2.5% MS because the marrow had aplastic anemia. The %MC was less than 20% in 89% (31/35), less than 10% in 77% (27/35), and less than 5% in 60% (21/35) of cases. The %MS was less than 10% in 91% (31/34), less than 5% in 85% (29/34), and less than 2% in 59% (20/34).
The quantities of the clones in the blood and marrow were compared for those cases with concurrent specimens ❚Table 4❚. The ACC correlated better with the %MS than CD16, and one case expressed CD16 without CD57. CD56 was expressed at least partially in 94% (46/49).
After clonality was defined by Vb, the clonal populations were backgated for comparison with the closest normal T lymphocytes (eg, CD8+ clones compared with normal CD8+ T cells in the same specimen), and it was found that, at times, there were clear differences from normal by more than 1/4 to 1/3 log immunofluorescence intensities that were not readily apparent before Vb analysis and backgating. Aberrant immunophenotypes, including those identified by backgating, were found on 94% (51/54) of LGLT clones ❚Table 2❚. The most common immunophenotypic abnormality was decreased or absent CD5, which was found in 63% (33/54), although slightly decreased CD5 was occasionally seen in polyclonal LGLTs (data not shown).
All cases had clonal abnormalities for Vb ❚Table 3❚. Restrictions for individual Vbs were found in 70% (38/54), although each Vb was found in less than 10% of cases. Lack of all tested 24 Vbs was found in 30% (16/54); this is considered abnormal because these 24 Vbs should be expressed by 70% of T lymphocytes. All clones expressed the ab T-cell receptor.
Size of the LGLT Clones
An absolute clone count (ACC) was calculated from the WBC count and from the percentage of clonal LGLTs in the blood ❚Figure 1❚. The ACC provided a better estimate of the size of the clone than the percentage because many of these patients had neutropenia. For example, one patient with 67% clonal LGLTs had an ACC of only 0.6 × 10 9 /L because the WBC count was only 0.9 × 10 9 /L. ACC was less than 2.0 × 10 9 /L in 76% (19/25) and less than 0.5 × 10 9 /L in 60% (15/25). © American Society for Clinical Pathology with the %MC. Most cases with large clones in the blood or marrow also had large clones at the other site. The ACC in the blood over time was generally stable, with limited follow-up, although there were exceptions, such as case 18, which had an increase from 6.9 to 40 × 10 9 /L over 63 months ❚Table 5❚. That patient had a history of rheumatoid arthritis and LGLT leukemia and was alive at last follow-up.
The quantity of the LGLT clone in the marrow over time was generally stable, with limited follow-up ❚Table 6❚, although there were exceptions. The %MS was more stable than the %MC. For example, during treatment for aplastic anemia, patient 2 had a %MC decrease from 33% to 5%, while the %MS changed only slightly from 2.5% to 0.4%. Patient 4 had kidney and liver transplants and LGLT leukemia and was treated for that but died at least in part due to leukemia 7 years after the original diagnosis.
Clinical Findings
The patients' ages ranged from 10 to 90 years, with a median of 68 years ❚Figure 3❚. Many of the patients were elderly. There were 50% males and 50% females. Anemia was found in 67% (16/24) of men, in 54% (13/24) of women, and in both children ❚Figure 4❚. Leukopenia and leukocytosis were found in 52% (26/50) and 16% (8/50), respectively ❚Figure 5❚. Neutropenia was present in 48% (24/50) and severe neutropenia (<0.5 × 10 9 /L) in 20% (10/50) ❚Figure 6❚. Most patients had thrombocytopenia (28/50 [56%]) ❚Figure 7❚.
Splenomegaly was detected in 14% (6/44) of patients. Four had large LGLT clones consistent with LGLT leukemia. A fifth had a myeloproliferative neoplasm, in addition to a 5% MS LGLT clone. A sixth patient with only slight splenomegaly had an ACC of 0.01 × 10 9 /L, 0.2% MS, and neutropenia and was treated with granulocyte colony-stimulating factor, prednisone, and cyclosporin A.
Many of these patients with LGLT clones had concurrent clinical disease: eight (15%) had B-cell clones, including posttransplant lymphoproliferative disorder of diffuse large B-cell lymphoma (n = 1), hairy cell leukemia (n = 1), marginal zone B-cell lymphoma (n = 1), CD5-/ LGLT, T-cell large granular lymphocyte; %MC, marrow leukocytes; %MS, marrow space. a Most of the LGLT clones were stable. CD10-mature B-cell clones (n = 2), CD10+ B-cell clone (n = 1), or B-cell lymphomas (n = 2). Seven patients (13%) had myeloid neoplasms, including myelodysplastic syndromes (n = 5), myeloproliferative neoplasm (n = 1), or unclassified myeloid neoplasm (n = 1). Another patient had received recent chemotherapy for acute myeloid leukemia. Seven patients (13%) had nonneoplastic diseases of the blood or marrow, including pure erythroid aplasia (n = 1), marrow agranulocytosis (n = 1), Evans syndrome (n = 1), or aplastic anemias (n = 4), including one associated with a 5% clone of paroxysmal nocturnal hemoglobinuria. Eight patients (15%) had received transplants, including heart (n = 1), kidney (n = 1), kidney and liver (n = 1), kidney and pancreas (n = 2), or bone marrow (n = 3). Eight patients (15%) had evidence of immune disorders, including rheumatoid arthritis (n = 5), polymyalgia rheumatica (n = 1), ulcerative colitis (n = 1), or antinuclear antibodies (n = 1). Five (9%) patients had carcinomas, including invasive ductal carcinoma of the breast (n = 1), colonic adenocarcinoma (n = 1), pulmonary adenocarcinoma (n = 1), metastatic renal cell carcinoma (n = 1), or metastatic small cell neuroendocrine carcinoma (n = 1). Twelve (22%) patients had hypothyroidism, and one had pulmonary hypertension thought to be due to the LGLT clone.
Ten (20%) of 51 patients had large LGLT clones: ACC greater than 2.0 × 10 9 /L or %MS greater than 10%. An additional two patients had clinical histories of LGLT leukemias; at the time of this study, one had 4.5% MS and 10% MC, and the other had 6% MS and 9.5% MC. For the patient groups described here and below, the immunophenotypic differences between groups were for abnormalities in CD3 and for lack of Vbs, and these will be described for each group. Among this group of patients, one LGLT clone had bright CD3, and four LGLT clones lacked all of the tested Vbs. Five cases tested by polymerase chain reaction (PCR) for rearrangement of the T-cell receptor g chain were monoclonal. Clinical follow-up was limited in this retrospective study, with only nine (18%) patients followed in the medical charts for more than 2 years, but three patients died at least in part due to LGLT leukemia at 7, 10, and 18 years after the original diagnosis; there was no splenomegaly or hepatomegaly at autopsy in one of those patients. A fourth patient with LGLT leukemia died, but the cause of death is unknown, and that patient had comorbidities, including renal failure and dementia.
Fifteen (29%) of 51 patients had small clones (ACC <2.0 × 10 9 /L and %MS <10%) and associated findings limited to nonneoplastic disorders of the blood or marrow (excluding aplastic anemia) or hypothyroidism. None of these patients died of the LGLT clone, and most (n = 10) received no drug therapy for the LGLT clone or the cytopenias according to the available medical records; these patients' ages ranged from 54 to 89 years. Most of these 10 patients had thrombocytopenia 4/7), anemia (6/7), neutropenia (3/7), or severe neutropenia (1/7). One LGLT clone had slightly dim CD3, and one LGLT clone lacked all of the tested Vbs. Two of these patients had more than one specimen tested over time, and those had stable levels of the LGLT clones over 7 to 25 months. One specimen tested by PCR for rearrangement of the T-cell receptor g chain was monoclonal.
Four of the 15 patients were treated for cytopenias with growth factors or steroids, and one had Evans syndrome and received rituximab. A fifth patient with slight splenomegaly was treated as described above. For these five patients, most had thrombocytopenia (3/5), anemia (2/5), neutropenia (3/5), or severe neutropenia (1/5). Three patients had more than one specimen tested over time, and those showed stable levels of the LGLT clones over 3 to 45 months.
Twenty-six (51%) of 51 patients had an ACC less than 2.0 × 10 9 /L, %MS less than 10%, and no clinical histories of LGLT leukemias but had clinically significant associated diseases other than those described above, and those other disorders could account for cytopenias. The patient ages ranged from 10 to 84 years, and eight patients were younger than 54 years. For these patients, about one-third (n = 11) had abnormal expression of CD3, either dim or bright, and about one-third (n = 10) had LGLT clones lacking all tested 24 Vbs. Eight of these patients had more than one specimen tested over time, and those had stable levels of the LGLT clones over 3 to 69 months, with a rare exception described below. Three patients had PCR performed for the T-cell receptor g chain, and two specimens were monoclonal; a third specimen from an aplastic marrow was oligoclonal. None of these patients had deaths that were attributed to the LGLT clone. The clinical management of these patients, however, was driven by treatment of the associated diseases, and some of those treatments could have effects on the LGLT clones, but it is not clear whether the clinical management of these patients was altered by knowledge of the presence of the small LGLT clones.
One patient, a 13-year-old girl, developed a posttransplant lymphoproliferative disorder of diffuse large B-cell lymphoma, as well as an LGLT clone with an ACC of 1.0 × 10 9 /L and 1% MS associated with an Epstein-Barr virus infection after bone marrow transplant for aplastic anemia. After treatment with rituximab, the size of the LGLT clone in the marrow decreased to 0.1% MS over 10 months.
Discussion
The 2008 WHO classification defines LGLT leukemia as a persistent increase in LGLTs greater than 2.0 × 10 9 /L in the blood without a known cause. 1 The current study confirms that ACC is a better indicator of clone size than the percentage of circulating leukocytes because many of these patients have neutropenia. 10 Similarly, the %MS is a better indicator of clone size than the %MC because many of these patients have hypocellular marrows, including aplastic anemia. In this study, large clones in the blood were generally associated with large clones in the marrow.
Once the clonality of LGLT is established, a 10-fold increase in the LGLT population would give an ACC greater than 2.0 × 10 9 /L or %MS greater than 10% (data not shown). If these criteria were used to define LGLT leukemia, 10 of the patients in this study would have leukemia, and an additional two patients had clinical histories of LGLT leukemias. Three of these patients had deaths due at least in part to the LGLT clone. Although splenomegaly is often associated with LGLT leukemias, it is interesting that one of the patients who died did not have splenomegaly or hepatomegaly at autopsy. The clinical course and treatment of LGLT leukemias have been reviewed elsewhere. 6, 11, 12 About one-third of the patients had small LGLT clones and associated diseases limited to nonneoplastic disorders of the blood or marrow (excluding aplastic anemia) or hypothyroidism. Most of these patients were monitored but not treated for the LGLT clone, but a minority received growth factors or steroids for cytopenias.
About half of the patients had small LGLT clones and clinically significant associated diseases: B-cell clones, myeloid neoplasms, aplastic anemia, transplants, systemic autoimmune disorders, or carcinomas. In these patients, the associated disease and its treatment dominated the clinical course. It is not clear whether the presence of small LGLT clones influenced the clinical management since some of the treatment regimens would be similar to those recommended for LGLT clones. Clinical diseases associated with LGLT clones have been reviewed elsewhere. 5, 6, [13] [14] [15] [16] [17] [18] [19] [20] For patients with small LGLT clones, we propose the term T-cell clone of undetermined significance, which is slightly different from T-cell clonopathy of undetermined significance, as will be discussed below. The precise size of the clone to distinguish LGLT leukemia from TCUS is not well defined and will likely evolve over time, but we propose a 10-fold increase, which would be an ACC greater than 2.0 × 10 9 /L or %MS greater than 10% for the leukemia. If the marrow cellularity were not available to calculate the %MS, then greater than 20% of marrow cells in an aspirate would be suggested, although this percentage might not reflect the true extent of marrow involvement in patients with hypocellular marrows, such as aplastic anemia. Documentation of the persistence of the clone for 6 months would be recommended.
Similar terminology is used for other disorders, such as monoclonal gammopathy of undetermined significance. Monoclonal B-cell lymphocytosis is essentially a B-cell clone of undetermined significance that is distinguished from chronic lymphocytic leukemia based on the size of the B-cell clone. The term leukemia is traditionally used for disorders with unregulated cellular proliferation as evidenced by large clones in the blood or marrow.
The term T-cell clonopathy of undetermined significance has been used in the medical literature for patients with varying sizes of LGLT clones to emphasize the indolent clinical course in many patients. 2, 3 Our proposed term would be restricted to those patients with small clones and omits the -opathy since some patients have no clinically significant disease, although the term T-cell clonopathy of undetermined significance has also been used for patients at the more benign end of the clinical spectrum. 2, 3, 21, 22 These small LGLT clones had aberrant immunophenotypes and clonal abnormalities by Vb. Most expressed CD8 without CD4, but a significant number coexpressed CD4 and CD8, as has been previously described. [23] [24] [25] Small LGLT clones have also been reported previously. 26, 27 Most of these small LGLT clones did not change the clinical management, but there may be patients who need treatment for an LGLT clone because of its immunologic effects, such as cytopenias, even if the clone size were small. Although these small clones with associated immunologic disease may be referred to in the medical literature as LGTL "leukemias," we propose that small clonal LGLTs associated with clinically significant immunologic effects be referred to as T-cell immunoclones. 6 The distinction between a TCUS and a TIC would be based on the clinical decision for a need to treat the immunologic effects of the LGLT clone, and then the term TIC could be applied rather than leukemia. The treatment would be because of the immunologic effects of the clone rather than its unregulated cellular proliferation. Similarly, the clinical need to treat autoimmune hemolytic anemia is not used to define the presence or absence of chronic lymphocytic leukemia in patients with monoclonal B-cell lymphocytosis. With extension of the terminology proposed here, monoclonal B-cell lymphocytosis would be a B-cell clone of undetermined significance, and if it were associated with an autoimmune hemolytic anemia that needed treatment, it would be considered a B-cell immunoclone. This proposed terminology for LGLT clones would then be more consistent with the terminology used for other leukemias and would still accommodate the need for treatment of the immunologic effects of TICs even if the size of the clones was not sufficient to diagnose LGLT leukemia. To summarize, the proposed terminology for the clinical spectrum of LGLT clones is TCUS,
LGLT leukemia, and TIC.
